Investors

Major active investors in Trinity Biosystems are Sanderling Ventures, SR One, Lilly Ventures, Life Science Partners and Amgen Ventures.

Sanderling Ventures
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Since its inception, Sanderling has supported over 40 biomedical companies from very early stages through commercial development. Sanderling emphasizes early-stage financing and active management of its portfolio companies. The Partnership has sufficient capital to support the companies in later-stage financing.

For more information on Sanderling Ventures, its staff and portfolio companies, please visit www.sanderling.com.

SR One
SR One is GlaxoSmithKline’s independent corporate healthcare venture capital fund. Based in West Conshohocken, PA, and London, U.K., SR One invests globally in emerging biotechnology companies that are engaged in drug discovery, development and delivery with the potential to yield dramatic patient benefits. Since its founding in 1985, SR One has placed over $475 million in more than 150 investments.

For more information on SR One, its staff and portfolio companies, please visit www.srone.com.

Lilly Ventures
Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. Lilly Ventures currently has $175M under management and focuses on three sectors: biotechnology, healthcare IT and medical technology.

For more information on Lilly Ventures, its staff and portfolio companies, please visit www.lillybioventures.com.

Life Science Partners
Life Sciences Partners (LSP) is a leading independent European venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With EUR 450 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors.

For more information on Life Science Partners, its staff and portfolio companies, please visit www.lspvc.com.

Amgen Ventures
With an initial investment of $100 million, the fund is designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures invests in early-stage biotechnology companies focused on discovering and developing human therapeutics. The fund, which focuses primarily on areas of current therapeutic interest to Amgen, offers early-stage companies access to Amgen’s extensive capabilities while providing Amgen with insight into external research innovations that may pave the way for future collaborations.

Amgen Ventures, based in San Diego, also leverages existing Amgen sites, including Seattle, San Francisco, Thousand Oaks, and Boston.